Cargando…
Exosome-transmitted miR-567 reverses trastuzumab resistance by inhibiting ATG5 in breast cancer
Trastuzumab is commonly used in the treatment of human epidermal growth factor receptor-2 positive (HER-2+) breast cancer, but its efficacy is often limited by the emergence of chemoresistance. Recent studies indicate that exosomes act as vehicles for exchange of genetic cargo between heterogeneous...
Autores principales: | Han, Mingli, Hu, Jianguo, Lu, Pengwei, Cao, Hui, Yu, Chao, Li, Xiangke, Qian, Xueke, Yang, Xue, Yang, Yunqing, Han, Na, Dou, Dongwei, Zhang, Fan, Ye, Mulin, Yang, Changcheng, Gu, Yuanting, Dong, Huaying |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6976584/ https://www.ncbi.nlm.nih.gov/pubmed/31969559 http://dx.doi.org/10.1038/s41419-020-2250-5 |
Ejemplares similares
-
Retraction Note: Exosome-transmitted miR-567 reverses trastuzumab resistance by inhibiting ATG5 in breast cancer
por: Han, Mingli, et al.
Publicado: (2023) -
Exosome-mediated lncRNA AFAP1-AS1 promotes trastuzumab resistance through binding with AUF1 and activating ERBB2 translation
por: Han, Mingli, et al.
Publicado: (2020) -
Retraction Note to: Exosome-mediated lncRNA AFAP1-AS1 promotes trastuzumab resistance through binding with AUF1 and activating ERBB2 translation
por: Han, Mingli, et al.
Publicado: (2022) -
Activation of LncRNA TINCR by H3K27 acetylation promotes Trastuzumab resistance and epithelial-mesenchymal transition by targeting MicroRNA-125b in breast Cancer
por: Dong, Huaying, et al.
Publicado: (2019) -
Correction to: Activation of LncRNA TINCR by H3K27 acetylation promotes Trastuzumab resistance and epithelial-mesenchymal transition by targeting MicroRNA-125b in breast Cancer
por: Dong, Huaying, et al.
Publicado: (2021)